Advertisement

Tumor Biology

, Volume 36, Issue 1, pp 227–231 | Cite as

Associations between the cytotoxic T lymphocyte antigen 4 polymorphisms and risk of bone sarcomas

Research Article
  • 141 Downloads

Abstract

Cytotoxic T lymphocyte antigen 4 (CTLA-4) genetic polymorphisms are implicated to be associated with susceptibility to bone sarcomas, but published studies have reported inconclusive results. The objective of our study was to conduct a meta-analysis investigating the associations between CTLA-4 gene polymorphisms and risk of bone sarcomas. PubMed and Embase databases were searched for all articles published up to June 2, 2013. Odds ratio (OR) with a 95 % confidence interval (95 % CI) was used to assess the association. Finally, 11 individual studies with a total of 2,951 cases with bone sarcomas and 3,396 controls were included in the meta-analysis. There were four studies on the CTLA-4 49G/A polymorphism, three studies on CTLA-4 318C/T polymorphism, two studies on CTLA-4 1661A/G polymorphism, and two studies on CTLA-4 60A/G polymorphism. Overall, CTLA-4 49G/A polymorphism was obviously associated with risk of bone sarcomas (A vs. G: OR = 1.36, 95 % CI = 1.20–1.54; AA vs. GG: OR = 2.24, 95 % CI = 1.67–2.99; AA vs. AG/GG: OR = 2.00, 95 % CI = 1.53–2.62; AA/GA vs. GG: OR = 1.35, 95 % CI = 1.14–1.61). However, CTLA-4 318C/T, 1661A/G, and 60A/G polymorphisms were not associated with risk of bone sarcomas. The current meta-analysis suggests that CTLA-4 49G/A polymorphism is obviously associated with risk of bone sarcomas. More studies are needed to further evaluate the associations between CTLA-4 polymorphisms and risk of bone sarcomas.

Keywords

CTLA-4 Bone sarcomas Polymorphism Meta-analysis 

Notes

Conflicts of interest

None.

References

  1. 1.
    Gaspar N, Di Giannatale A, Geoerger B, Redini F, Corradini N, Enz-Werle N, et al. Bone sarcomas: from biology to targeted therapies. Sarcoma. 2012;2012:301975.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Whelan J, McTiernan A, Cooper N, Wong YK, Francis M, Vernon S, et al. Incidence and survival of malignant bone sarcomas in England 1979–2007. Int J Cancer. 2012;131:E508–17.CrossRefPubMedGoogle Scholar
  3. 3.
    ESMO/European Sarcoma Network Working Group. Bone sarcomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii100–9.Google Scholar
  4. 4.
    Yarber JL, Agulnik M. Targeted therapies in bone sarcomas: Current approach and future directions. Expert Opin Investig Drugs. 2011;20:973–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Grimer R, Athanasou N, Gerrand C, Judson I, Lewis I, Morland B, et al. UK guidelines for the management of bone sarcomas. Sarcoma. 2010;2010:317462.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013;13:227–42.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Ghalamfarsa G, Hadinia A, Yousefi M, Jadidi-Niaragh F. The role of natural killer T cells in B cell malignancies. Tumour Biol. 2013;34:1349–60.CrossRefPubMedGoogle Scholar
  8. 8.
    Ramakrishnan R, Gabrilovich DI. Novel mechanism of synergistic effects of conventional chemotherapy and immune therapy of cancer. Cancer Immunol Immunother. 2013;62:405–10.CrossRefPubMedGoogle Scholar
  9. 9.
    Deluca DS, Blasczyk R. The immunoinformatics of cancer immunotherapy. Tissue Antigens. 2007;70:265–71.CrossRefPubMedGoogle Scholar
  10. 10.
    Ghaderi A. CTLA4 gene variants in autoimmunity and cancer: a comparative review. Iran J Immunol. 2011;8:127–49.PubMedGoogle Scholar
  11. 11.
    Monjazeb AM, Hsiao HH, Sckisel GD, Murphy WJ. The role of antigen-specific and non-specific immunotherapy in the treatment of cancer. J Immunotoxicol. 2012;9:248–58.CrossRefPubMedGoogle Scholar
  12. 12.
    Lens M, Testori A, Ferucci PF. Ipilimumab targeting CD28-CTLA-4 axis: New hope in the treatment of melanoma. Curr Top Med Chem. 2012;12:61–6.CrossRefPubMedGoogle Scholar
  13. 13.
    Schmetterer KG, Neunkirchner A, Pickl WF. Naturally occurring regulatory T cells: Markers, mechanisms, and manipulation. FASEB J. 2012;26:2253–76.CrossRefPubMedGoogle Scholar
  14. 14.
    Tang ST, Tang HQ, Zhang Q, Wang CJ, Wang YM, Peng WJ. Association of cytotoxic T-lymphocyte associated antigen 4 gene polymorphism with type 1 diabetes mellitus: a meta-analysis. Gene. 2012;508:165–87.CrossRefPubMedGoogle Scholar
  15. 15.
    Romo-Tena J, Gomez-Martin D, Alcocer-Varela J. CTLA-4 and autoimmunity: new insights into the dual regulator of tolerance. Autoimmun Rev. 2013;12:1171-6. .Google Scholar
  16. 16.
    Sun T, Hu Z, Shen H, Lin D. Genetic polymorphisms in cytotoxic t-lymphocyte antigen 4 and cancer: the dialectical nature of subtle human immune dysregulation. Cancer Res. 2009;69:6011–4.CrossRefPubMedGoogle Scholar
  17. 17.
    Li M, Zheng H, Li T, Gao P, Zhang XL, Liu DW. Cytotoxic T-lymphocyte associated antigen-4 gene polymorphisms and primary biliary cirrhosis: a systematic review. J Gastroenterol Hepatol. 2012;27:1159–66.CrossRefPubMedGoogle Scholar
  18. 18.
    Liu Y, He Z, Feng D, Shi G, Gao R, Wu X, et al. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to osteosarcoma. DNA Cell Biol. 2011;30:1051–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Wang W, Wang J, Song H, Liu J, Song B, Cao X. Cytotoxic T-lymphocyte antigen-4 + 49G/A polymorphism is associated with increased risk of osteosarcoma. Genet Test Mol Biomarkers. 2011;15:503–6.CrossRefPubMedGoogle Scholar
  20. 20.
    Yang S, Wang C, Zhou Y, Sun G, Zhu D, Gao S. Cytotoxic T-lymphocyte antigen-4 polymorphisms and susceptibility to Ewing’s sarcoma. Genet Test Mol Biomarkers. 2012;16:1236–40.CrossRefPubMedGoogle Scholar
  21. 21.
    Feng D, Yang X, Li S, Liu T, Wu Z, Song Y, et al. Cytotoxic T-lymphocyte antigen-4 genetic variants and risk of Ewing’s sarcoma. Genet Test Mol Biomarkers. 2013;17:458–63.CrossRefPubMedGoogle Scholar
  22. 22.
    Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177–88.CrossRefPubMedGoogle Scholar
  24. 24.
    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22:719–48.PubMedGoogle Scholar
  25. 25.
    Yang M, Sun T, Zhou Y, Wang L, Liu L, Zhang X, et al. The functional cytotoxic T lymphocyte-associated protein 4 49G-to-A genetic variant and risk of pancreatic cancer. Cancer. 2012;118:4681–6.CrossRefPubMedGoogle Scholar
  26. 26.
    Bharti V, Mohanti BK, Das SN. Functional genetic variants of CTLA-4 and risk of tobacco-related oral carcinoma in high-risk North Indian population. Hum Immunol. 2013;74:348–52.CrossRefPubMedGoogle Scholar
  27. 27.
    Gokhale P, Kerkar S, Tongaonkar H, Salvi V, Mania-Pramanik J. CTLA-4 gene polymorphism at position +49 A > G in exon 1: a risk factor for cervical cancer in Indian women. Cancer Genet. 2013;206:154–61.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  1. 1.Department of Orthopaedic SurgeryGeneral Hospital of Jinan Military CommandJinanChina
  2. 2.Department of Orthopaedic Surgerythe Third Hospital of Jinan CityJinanChina
  3. 3.Department of Orthopaedic SurgeryNo. 3 People’s Hospital Affiliated to Shang Hai Jiao Tong University School of MedicineShanghaiChina

Personalised recommendations